Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Triaziquone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 2/20 | 0.60 |
| ▸ | BTK known ✓ | Q06187 | 2/20 | 0.60 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.60 |
| ▸ | ERBB4 known ✓ | Q15303 | 1/20 | 0.60 |
| ▸ | MTOR known ✓ | P42345 | 1/20 | 0.52 |
| ▸ | HCK | P08631 | 16/20 | 0.72 |
| ▸ | FLT3 | P36888 | 10/20 | 0.60 |
| ▸ | LCK | P06239 | 5/20 | 0.60 |
| ▸ | SRC | P12931 | 5/20 | 0.60 |
| ▸ | TEK | Q02763 | 5/20 | 0.60 |
| ▸ | KDR | P35968 | 4/20 | 0.60 |
| ▸ | FYN | P06241 | 2/20 | 0.60 |
| ▸ | LYN | P07948 | 2/20 | 0.60 |
| ▸ | CSK | P41240 | 2/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.60 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.60 |
| ▸ | PLK4 | O00444 | 1/20 | 0.60 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.60 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL6464977 | 0.91 | HCK (0.88) | HCKFLT3LCKSRCTEK | |
| Maleic Acid SCHEMBL6464975 | 0.91 | HCK (0.88) | HCKFLT3LCKSRCTEK | |
| Maleic Acid SCHEMBL6459065 | 0.91 | HCK (0.88) | HCKFLT3LCKSRCTEK | |
| Fumaric Acid SCHEMBL6459070 | 0.91 | HCK (0.88) | HCKFLT3LCKSRCTEK | |
| Triaziquone SCHEMBL6465391 | 0.90 | HCK (0.63) | HCKFLT3LCKSRCTEK | |
| SCHEMBL6460510 | 0.85 | HCK (1.00) | HCKFLT3LCKSRCTEK | |
| SCHEMBL6461019 | 0.85 | HCK (1.00) | HCKFLT3LCKSRCTEK | |
| SCHEMBL6460515 | 0.85 | HCK (1.00) | HCKFLT3LCKSRCTEK | |
| Maleic Acid SCHEMBL6465396 | 0.78 | HCK (0.76) | HCKFLT3LCKSRCTEK | |
| Fumaric Acid SCHEMBL6467943 | 0.78 | HCK (0.76) | HCKFLT3LCKSRCTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713474-B2 | SERINE-THREONINE AND TYROSINE KINASE INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2004-03-30 | — | — | US | claimed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | claimed |
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| WO-2004100868-A2 | METHOD OF TREATING TRANSPLANT REJECTION | ABBOTT LABORATORIES (US) | 2004-11-25 | — | — | WO | disclosed |
| US-6713474-B2 | SERINE-THREONINE AND TYROSINE KINASE INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2004-03-30 | — | — | US | disclosed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | disclosed |
| EP-1114053-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000017203-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | EGFR 818/4885BTK 42/4885ERBB2 894/4885 |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | FLT1, FLT4, TFPI | EGFR 457/4885BTK 117/4885ERBB2 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.